Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2013 Sep 26;369(13):1278-9.
doi: 10.1056/NEJMc1309710.

Ibrutinib in relapsed chronic lymphocytic leukemia

John C Byrd, Susan O'Brien, Danelle F James
Comment

Ibrutinib in relapsed chronic lymphocytic leukemia

John C Byrd et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Comment on

  • Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
    Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O'Brien S. Byrd JC, et al. N Engl J Med. 2013 Jul 4;369(1):32-42. doi: 10.1056/NEJMoa1215637. Epub 2013 Jun 19. N Engl J Med. 2013. PMID: 23782158 Free PMC article. Clinical Trial.
  • Ibrutinib in relapsed chronic lymphocytic leukemia.
    Neffendorf JE, Gout I, Hildebrand GD. Neffendorf JE, et al. N Engl J Med. 2013 Sep 26;369(13):1277. doi: 10.1056/NEJMc1309710. N Engl J Med. 2013. PMID: 24066759 No abstract available.
  • Ibrutinib in relapsed chronic lymphocytic leukemia.
    Rushworth SA, MacEwan DJ, Bowles KM. Rushworth SA, et al. N Engl J Med. 2013 Sep 26;369(13):1277-8. doi: 10.1056/NEJMc1309710. N Engl J Med. 2013. PMID: 24066760 No abstract available.

MeSH terms

LinkOut - more resources